Our Clinical Trials
20180146
Prostate CancerA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Lines of Therapy: OtherC1071007 MagnetisMM-7
Multiple MyelomaA RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Lines of Therapy: OtherD419ML00003 TRITON
Lung CancerA Phase IIIb, Randomized, Multicenter, Open-lable Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Bases Chemotherapy for First-Line Treatment in Metastatic No-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutation in STK11, KEAP1 or KRAS.
Lines of Therapy: 1st Line Metastatic and Locally AdvancedFLM-6774-201 PEMDA-HN
Head and Neck CancerAn Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lines of Therapy: 1st Line Metastatic and Locally AdvancedPRESERVE-003 (LUN 514)
Lung CancerPhase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Lines of Therapy: 2nd Line Metastatic